Developing Novel Immunotherapeutics for Acute Myeloid Leukemia
Abstract
Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults and the second most common pediatric leukemia. The goal of this funded project is to develop novel form of therapeutic agents for selective killing of AML cells through activating and redirecting cellular immunity. This will be achieved by exploiting a multidisciplinary approach to design, generate, and characterize the proposed therapeutic exosomes using cellular and animal models of AML. During the second year of the performance period, we designed and generated genetically engineered exosomes with immunomodulatory agents. By evaluating physicochemical properties and biological activities of various types of genetically modified exosomes, designed constructs with important functions and properties were identified. Lead candidate exosomes are being studied for pharmacological activities as well as mechanisms of action using cellular and animal models of AML.
Document Details
- Document Type
- Technical Report
- Publication Date
- Jul 01, 2021
- Accession Number
- AD1152593
Entities
People
- Yong Zhang
Organizations
- University of Southern California